JCO correspondence centers on progression assessment in advanced prostate cancer
This Journal of Clinical Oncology correspondence is a reply to the article titled “Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.” The publication record available in the scraped text identifies the piece as a correspondence item dated July 31, 2026, with a DOI of 10.1200/JCO-26-01500. The author group includes Andrew J. Armstrong, Arun A. Azad, Fred Saad, Maha Hussain, Taro Iguchi, Arnulf Stenzl, and Cora N. Sternberg.
The accessible text does not include the body of the reply, the underlying data being discussed, or any numerical results. What is available is the article framing, the link to the accompanying primary correspondence, and the disclosure section. In a clinical journal, that matters because a reply of this kind usually addresses interpretation, methodology, or disease-monitoring implications rather than introducing a new dataset of its own. Here, the central topic is clear from the title alone: how advanced prostate cancer progression is recognized when patients are treated with enzalutamide, and how imaging change may or may not align with prostate-specific antigen behavior.
Radiographic progression and PSA kinetics often travel together in prostate oncology, but they do not always rise and fall in lockstep. When they diverge, clinicians are forced to decide whether disease is evolving biologically before the biomarker signals catch up, or whether the biomarker is failing to capture a clinically meaningful change in tumor burden. In practice, that question affects when imaging is ordered, when treatment is changed, and how long a regimen is continued in the face of ambiguous laboratory trends.
The correspondence format itself signals an important feature of modern oncology discourse: a single monitoring marker rarely settles the question on its own. PSA is deeply embedded in prostate cancer care because it is easy to measure and often tracks response, yet tumor biology can outpace marker behavior, especially in advanced disease. Imaging, by contrast, captures structural progression, but it can also introduce uncertainty when lesions are subtle, mixed, or difficult to compare across scans. The tension between those two readouts is exactly the kind of issue that prompts peer commentary in a journal like JCO.
This publication also lists the authors’ conflict-of-interest disclosures in detail. Andrew J. Armstrong reports consulting roles with Bayer, Pfizer, Astellas Scientific and Medical Affairs Inc, AstraZeneca, Merck, Bristol Myers Squibb, Janssen, Novartis, Exelixis, Myovant Sciences, Precede Bio, Sumitomo Pharma Oncology, and Boundless Bio, along with multiple research funding relationships. Arun A. Azad reports honoraria, consulting roles, speakers’ bureau participation, and research funding across a broad set of oncology companies. For readers, those disclosures do not invalidate the correspondence, but they are part of the transparency that surrounds contemporary oncology scholarship, especially when the discussion touches a widely used androgen receptor pathway inhibitor such as enzalutamide.
The absence of the full reply text limits any deeper appraisal of the authors’ argument, and it also prevents a responsible reconstruction of the specific points they made about progression timing, PSA discordance, or imaging interpretation. No trial design, sample size, endpoint definitions, or patient characteristics are visible in the scraped body. Without those details, the safest reading is straightforward: this is a scholarly exchange about how best to interpret progression in men with advanced prostate cancer receiving enzalutamide, and the article record itself does not provide the underlying evidentiary content needed to go further.
One sentence captures the practical stakes. When PSA and scans disagree, treatment decisions can become uncomfortably dependent on which signal is trusted most.
For clinicians, that kind of disagreement is not an academic curiosity. It affects surveillance intensity, the threshold for switching therapy, and the confidence with which a rising biomarker is treated as biologic progression rather than laboratory noise. In advanced prostate cancer, where sequential lines of therapy are common and resistance mechanisms can emerge silently, discordant monitoring deserves close attention even when a correspondence item does not supply new outcome data.
Disclosures and article status define the limits of interpretation
The publication record available here is incomplete from a clinical reporting standpoint. It contains the title, authorship, date, DOI, and disclosures, but not the text of the correspondence itself. As a result, this piece cannot be summarized as though it presented a trial result, a new subgroup analysis, or a practice-changing conclusion.
What can be stated with confidence is narrower: the correspondence belongs to the ongoing discussion around radiographic progression versus PSA rise in men with advanced prostate cancer treated with enzalutamide. The unresolved question for readers is not whether the topic matters, but which imaging and biomarker signals should drive the next therapeutic decision when they move in different directions. That answer would require the full correspondence text and, ideally, the accompanying primary article it addresses.